269 related articles for article (PubMed ID: 28975580)
1. Vitamin D and disability in relapsing-remitting multiple sclerosis in patients with a Mexican background.
Rito Y; Flores J; Fernández-Aguilar A; Escalante-Membrillo C; Barboza MA; Amezcua L; Corona T
Acta Neurol Belg; 2018 Mar; 118(1):47-52. PubMed ID: 28975580
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis.
Thouvenot E; Orsini M; Daures JP; Camu W
Eur J Neurol; 2015 Mar; 22(3):564-9. PubMed ID: 25530281
[TBL] [Abstract][Full Text] [Related]
3. Association of seasonal serum 25-hydroxyvitamin D levels with disability and relapses in relapsing-remitting multiple sclerosis.
Brola W; Sobolewski P; Szczuchniak W; Góral A; Fudala M; Przybylski W; Opara J
Eur J Clin Nutr; 2016 Sep; 70(9):995-9. PubMed ID: 27026420
[TBL] [Abstract][Full Text] [Related]
4. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis.
Smolders J; Menheere P; Kessels A; Damoiseaux J; Hupperts R
Mult Scler; 2008 Nov; 14(9):1220-4. PubMed ID: 18653736
[TBL] [Abstract][Full Text] [Related]
5. Lack of association between vitamin D levels and bone mineral density in patients with multiple sclerosis.
Triantafyllou N; Lambrinoudaki I; Thoda P; Andreadou E; Kararizou E; Alexandrou A; Limouris G; Antoniou A; Tsivgoulis G
J Neurol Sci; 2012 Feb; 313(1-2):137-41. PubMed ID: 21992813
[TBL] [Abstract][Full Text] [Related]
6. Bone metabolism and vitamin D status in patients with multiple sclerosis.
Kępczyńska K; Zajda M; Lewandowski Z; Przedlacki J; Zakrzewska-Pniewska B
Neurol Neurochir Pol; 2016; 50(4):251-7. PubMed ID: 27375138
[TBL] [Abstract][Full Text] [Related]
7. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
[TBL] [Abstract][Full Text] [Related]
8. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.
Kallweit U; Jelcic I; Braun N; Fischer H; Zörner B; Schreiner B; Sokolov AA; Martin R; Weller M; Linnebank M
Clin Neuropharmacol; 2012; 35(2):77-80. PubMed ID: 22318192
[TBL] [Abstract][Full Text] [Related]
9. Hypovitaminosis D association with disease activity in relapsing remitting multiple sclerosis in Brazil.
Becker J; Callegaro D; Lana-Peixoto MA; Talim N; Vidaletti T; de Paula Corrêa M; Gomes I
J Neurol Sci; 2016 Apr; 363():236-9. PubMed ID: 27000256
[TBL] [Abstract][Full Text] [Related]
10. Effect of vitamin D replacement on depression in multiple sclerosis patients.
Kotb MA; Kamal AM; Aldossary NM; Bedewi MA
Mult Scler Relat Disord; 2019 Apr; 29():111-117. PubMed ID: 30708308
[TBL] [Abstract][Full Text] [Related]
11. Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients.
Cavallari M; Palotai M; Glanz BI; Egorova S; Prieto JC; Healy BC; Chitnis T; Guttmann CR
Mult Scler; 2016 Dec; 22(14):1841-1849. PubMed ID: 26920374
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab.
Laursen JH; Søndergaard HB; Sørensen PS; Sellebjerg F; Oturai AB
Mult Scler Relat Disord; 2016 Nov; 10():169-173. PubMed ID: 27919484
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D and body mass index in Egyptian multiple sclerosis patients.
Zamzam D; Foad M; Swelam M; AbdelHafez M; AbdelNasser A; Mahmoud R; Aref H; Zakaria M
Mult Scler Relat Disord; 2019 Feb; 28():313-316. PubMed ID: 30823981
[TBL] [Abstract][Full Text] [Related]
14. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.
Young PJ; Lederer C; Eder K; Daumer M; Neiss A; Polman C; Kappos L;
Neurology; 2006 Sep; 67(5):804-8. PubMed ID: 16966541
[TBL] [Abstract][Full Text] [Related]
15. Association of vitamin D status and clinical and radiological outcomes in a treated MS population in Poland.
Wawrzyniak S; Mikołajewska E; Kuczko-Piekarska E; Niezgodzińska-Maciejek A; Goch A
Brain Behav; 2017 Feb; 7(2):e00609. PubMed ID: 28239520
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients.
Lanzillo R; Di Somma C; Quarantelli M; Ventrella G; Gasperi M; Prinster A; Vacca G; Pivonello C; Orefice G; Colao A; Morra VB
Eur J Neurol; 2011 Dec; 18(12):1402-6. PubMed ID: 21585623
[TBL] [Abstract][Full Text] [Related]
17. Association of sex hormones and glucose metabolism with the severity of multiple sclerosis.
Triantafyllou N; Thoda P; Armeni E; Rizos D; Kaparos G; Augoulea A; Alexandrou A; Creatsa M; Tsivgoulis G; Artemiades A; Panoulis C; Lambrinoudaki I
Int J Neurosci; 2016 Sep; 126(9):797-804. PubMed ID: 26407165
[TBL] [Abstract][Full Text] [Related]
18. Latitude, sun exposure and vitamin D supplementation: associations with quality of life and disease outcomes in a large international cohort of people with multiple sclerosis.
Jelinek GA; Marck CH; Weiland TJ; Pereira N; van der Meer DM; Hadgkiss EJ
BMC Neurol; 2015 Aug; 15():132. PubMed ID: 26243188
[TBL] [Abstract][Full Text] [Related]
19. Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients.
Bove R; Healy BC; Musallam A; Soltany P; Diaz-Cruz C; Sattarnezhad N; Glanz BI; Kivisäkk P; Miller KK; Chitnis T
Mult Scler; 2019 Mar; 25(3):344-351. PubMed ID: 29320952
[TBL] [Abstract][Full Text] [Related]
20. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
